Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $242.00

Neurocrine Biosciences (NASDAQ:NBIX) had its target price raised by stock analysts at Citigroup from $204.00 to $242.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s price objective suggests a potential upside of 84.99% from the stock’s previous close.

NBIX has been the topic of a number of other research reports. BMO Capital Markets reduced their price objective on Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating on the stock in a research note on Thursday, February 12th. Canaccord Genuity Group lifted their price objective on Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday. Royal Bank Of Canada reduced their price objective on Neurocrine Biosciences from $180.00 to $177.00 and set an “outperform” rating on the stock in a research note on Thursday, February 12th. Stifel Nicolaus lifted their price objective on Neurocrine Biosciences from $183.00 to $188.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Finally, UBS Group reduced their price objective on Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $180.70.

Neurocrine Biosciences Trading Down 1.3%

NBIX traded down $1.67 on Tuesday, hitting $130.82. 890,760 shares of the company’s stock traded hands, compared to its average volume of 1,143,899. The company’s 50 day simple moving average is $131.52 and its 200-day simple moving average is $139.01. The firm has a market cap of $13.13 billion, a price-to-earnings ratio of 28.08, a P/E/G ratio of 0.69 and a beta of 0.35. Neurocrine Biosciences has a one year low of $84.23 and a one year high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.36 by ($0.48). Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The business had revenue of $805.50 million for the quarter, compared to the consensus estimate of $804.21 million. During the same period last year, the business posted $1.69 EPS. The firm’s revenue for the quarter was up 28.3% compared to the same quarter last year. As a group, equities analysts anticipate that Neurocrine Biosciences will post 4.28 EPS for the current fiscal year.

Insider Activity at Neurocrine Biosciences

In other news, CEO Kyle Gano sold 36,400 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the transaction, the chief executive officer owned 140,407 shares in the company, valued at approximately $18,632,008.90. The trade was a 20.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of NBIX. Royal Bank of Canada boosted its holdings in shares of Neurocrine Biosciences by 36.7% in the 1st quarter. Royal Bank of Canada now owns 82,810 shares of the company’s stock worth $9,158,000 after purchasing an additional 22,224 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Neurocrine Biosciences by 60.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,783 shares of the company’s stock worth $1,647,000 after purchasing an additional 5,577 shares during the period. NewEdge Advisors LLC boosted its holdings in Neurocrine Biosciences by 56.3% during the 1st quarter. NewEdge Advisors LLC now owns 7,630 shares of the company’s stock valued at $844,000 after acquiring an additional 2,747 shares during the period. Empowered Funds LLC purchased a new position in Neurocrine Biosciences during the 1st quarter valued at $1,333,000. Finally, Geneos Wealth Management Inc. boosted its holdings in Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Several analysts boosted ratings and price targets on NBIX, citing the Soleno deal and VYKAT XR upside — examples include Canaccord raising its target to $200 (buy), HC Wainwright to $215 (buy), Wedbush to $166 (outperform), Bank of America to $199 (buy) and Needham reaffirming buy at $185. These upgrades signal Wall Street sees meaningful revenue and strategic upside from the acquisition. Benzinga Ticker Report TipRanks / BofA note
• Neutral Sentiment: Neurocrine agreed to acquire Soleno Therapeutics for about $2.9 billion in cash at $53.00/sh, adding VYKAT™ XR (first‑approved therapy for hyperphagia in Prader‑Willi) and expanding into metabolic/endocrinology and rare disease — management highlights potential for a durable growth platform and will host a conference call to discuss details. PR Newswire Reuters
• Negative Sentiment: Investors pushed NBIX lower after the announcement — reasons include the hefty cash outlay, integration and execution risk, and analyst caution about a near‑term pipeline lull; BMO kept a Hold at $140, highlighting offsetting risks despite the acquisition thesis. The market reaction also reflects Soleno shares jumping sharply on the premium while acquirer NBIX retrenched. TipRanks / BMO note Barron’s

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.